Ciraparantag is primarily investigated for its potential use as a reversal agent for anticoagulant therapies. It is designed to neutralize the effects of certain anticoagulants, particularly those that inhibit factor Xa and thrombin, which are critical in the blood clotting process. This makes it a promising candidate in emergency situations where rapid reversal of anticoagulation is necessary, such as in cases of uncontrolled bleeding or prior to urgent surgical procedures. Its broad-spectrum activity could offer an advantage over existing reversal agents, which are often specific to a single type of anticoagulant. Research is ongoing to evaluate its efficacy and safety in clinical settings.